Aragen Unveils US$ 3M Formulations Manufacturing Hub - News

Aragen Life Sciences Ltd, a key player in pharmaceutical research and manufacturing services, has inaugurated its formulations manufacturing facility in Hyderabad, marking a US$ 3 million investment. 
Expanding Aragen’s New Chemical Entity (NCE) early-stage development capabilities, this cutting-edge facility covers 12,000 sq ft at the Mallapur Campus. It’s designed for clinical manufacturing of diverse dosage forms, including oral solids, liquids, topicals, and films. 
Manni Kantipudi, CEO, Aragen Life Sciences, stated that this expansion broadens their service spectrum, offering customers integrated solutions from early-stage development to clinical manufacturing within a single facility. The facility incorporates advanced formulation technologies, ensuring the company’s leadership in pharmaceutical innovation, and is already approved by Indian regulators, CDSCO, and DCA. With flexible batch sizes and a dedicated team of around 60 professionals, Aragen is poised to elevate its position in pharmaceutical research and manufacturing services.